Disease on EC 1.14.11.66 - [histone H3]-trimethyl-L-lysine9 demethylase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Adenocarcinoma
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Adenocarcinoma
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Adenocarcinoma
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Adenocarcinoma
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Adenocarcinoma
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Adenocarcinoma of Lung
Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.
Adenocarcinoma of Lung
KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp3 transcription in lung adenocarcinoma cells.
Adenocarcinoma of Lung
LSD1 inhibition attenuates tumor growth by disrupting PLK1 mitotic pathway.
Adenocarcinoma of Lung
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Alzheimer Disease
The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration.
Anemia, Sickle Cell
RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases ?-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
Aortic Aneurysm, Abdominal
Inhibition of macrophage histone demethylase JMJD3 protects against abdominal aortic aneurysms.
Arsenic Poisoning
Histone demethylase JHDM2A regulates H3K9 dimethylation in response to arsenic-induced DNA damage and repair in normal human liver cells.
Arthritis, Rheumatoid
Cystathionine-?-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis.
Arthritis, Rheumatoid
Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis.
Arthritis, Rheumatoid
Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells.
Asthma
IL-13 Augments Histone Demethylase JMJD2B/KDM4B Expression Levels, Activity, and Nuclear Translocation in Airway Fibroblasts in Asthma.
Azoospermia
Expression ratio of histone demethylase KDM3A to protamine-1 mRNA is predictive of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia.
Azoospermia
Hsa-miR-27a-3p overexpression in men with nonobstructive azoospermia: A case-control study.
Azoospermia
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Blast Crisis
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Blast Crisis
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Bone Neoplasms
Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats.
Brain Ischemia
Distribution of lysine-specific demethylase 1 in the brain of rat and its response in transient global cerebral ischemia.
Brain Neoplasms
The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin Association and Epithelial-to-mesenchymal Transition.
Breast Neoplasms
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
Breast Neoplasms
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.
Breast Neoplasms
An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde in Living Cells.
Breast Neoplasms
Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.
Breast Neoplasms
Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.
Breast Neoplasms
Comparison of the expression levels of lysine-specific demethylase 1 and survival outcomes between triple-negative and non-triple-negative breast cancer.
Breast Neoplasms
Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase.
Breast Neoplasms
Corrigendum: The Jumonji Domain-Containing Histone Demethylase Homolog 1D/lysine Demethylase 7A (JHDM1D/KDM7A) Is an Epigenetic Activator of RHOJ Transcription in Breast Cancer Cells.
Breast Neoplasms
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Breast Neoplasms
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor ? (ER?) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
Breast Neoplasms
Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7.
Breast Neoplasms
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Breast Neoplasms
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
Breast Neoplasms
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
Breast Neoplasms
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Breast Neoplasms
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Breast Neoplasms
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Breast Neoplasms
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Breast Neoplasms
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Breast Neoplasms
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Breast Neoplasms
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Breast Neoplasms
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Breast Neoplasms
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Breast Neoplasms
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Breast Neoplasms
Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.
Breast Neoplasms
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Breast Neoplasms
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Breast Neoplasms
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Breast Neoplasms
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
Breast Neoplasms
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.
Breast Neoplasms
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
Breast Neoplasms
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Breast Neoplasms
LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.
Breast Neoplasms
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Breast Neoplasms
Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer.
Breast Neoplasms
Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats.
Breast Neoplasms
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Breast Neoplasms
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Breast Neoplasms
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
Breast Neoplasms
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Breast Neoplasms
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Breast Neoplasms
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Breast Neoplasms
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Breast Neoplasms
Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells.
Breast Neoplasms
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Breast Neoplasms
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Breast Neoplasms
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Breast Neoplasms
T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.
Breast Neoplasms
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
Breast Neoplasms
The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.
Breast Neoplasms
The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer.
Breast Neoplasms
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
Breast Neoplasms
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
Breast Neoplasms
The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells.
Breast Neoplasms
The Histone Demethylase LSD1/?DM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program.
Breast Neoplasms
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
Breast Neoplasms
The Jumonji Domain-Containing Histone Demethylase Homolog 1D/lysine Demethylase 7A (JHDM1D/KDM7A) Is an Epigenetic Activator of RHOJ Transcription in Breast Cancer Cells.
Breast Neoplasms
The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
Breast Neoplasms
The R251Q mutation of LSD1 promotes invasion and migration of luminal breast cancer cells.
Breast Neoplasms
The zinc-finger transcriptional factor Slug transcriptionally downregulates ER? by recruiting lysine-specific demethylase 1 in human breast cancer.
Breast Neoplasms
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
Breast Neoplasms
UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor.
Breast Neoplasms
[Knockdown of lysine-specific demethylase 3A (KDM3A) inhibits the invasion and migration of MDA-MB-231 breast cancer cells and arrests the cell cycle in the G0/G1 phase].
Carcinogenesis
A developmental genetic analysis of the lysine demethylase KDM2 mutations in Drosophila melanogaster.
Carcinogenesis
Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A.
Carcinogenesis
Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Carcinogenesis
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Carcinogenesis
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.
Carcinogenesis
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Carcinogenesis
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Carcinogenesis
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Carcinogenesis
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Carcinogenesis
Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma.
Carcinogenesis
E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
Carcinogenesis
Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.
Carcinogenesis
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
Carcinogenesis
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Carcinogenesis
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
Carcinogenesis
High-Throughput TR-FRET Assays for Identifying Inhibitors of LSD1 and JMJD2C Histone Lysine Demethylases.
Carcinogenesis
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Carcinogenesis
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Carcinogenesis
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Carcinogenesis
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Carcinogenesis
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Carcinogenesis
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Carcinogenesis
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Carcinogenesis
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Carcinogenesis
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Carcinogenesis
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Carcinogenesis
Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers.
Carcinogenesis
In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.
Carcinogenesis
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Carcinogenesis
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Carcinogenesis
IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.
Carcinogenesis
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
Carcinogenesis
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
Carcinogenesis
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Carcinogenesis
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Carcinogenesis
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Carcinogenesis
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
Carcinogenesis
KDM4A regulates myogenesis by demethylating H3K9me3 of myogenic regulatory factors.
Carcinogenesis
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Carcinogenesis
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Carcinogenesis
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Carcinogenesis
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
Carcinogenesis
Lysine-specific demethylase 1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt/?-catenin pathway by down-regulating Dickkopf-1 (DKK1).
Carcinogenesis
Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele.
Carcinogenesis
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
Carcinogenesis
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
Carcinogenesis
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Carcinogenesis
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Carcinogenesis
Nuclear GSK3? promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.
Carcinogenesis
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Carcinogenesis
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Carcinogenesis
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Carcinogenesis
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Carcinogenesis
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
Carcinogenesis
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
Carcinogenesis
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Carcinogenesis
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
Carcinogenesis
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Carcinogenesis
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
Carcinogenesis
The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Carcinogenesis
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Carcinogenesis
Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1.
Carcinogenesis
ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.
Carcinoma
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Carcinoma
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
Carcinoma
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Carcinoma
Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells.
Carcinoma
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
Carcinoma
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Carcinoma
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Carcinoma
Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Carcinoma
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
Carcinoma
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Carcinoma
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Carcinoma
Lysine demethylase 3a in craniofacial and neural development during Xenopus embryogenesis.
Carcinoma
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Carcinoma
Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.
Carcinoma
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Carcinoma
Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.
Carcinoma
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Carcinoma
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
Carcinoma
Regulation of the Histone Demethylase JMJD1A by HIF-1{alpha} Enhances Hypoxic Gene Expression and Tumor Growth.
Carcinoma
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
Carcinoma
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
Carcinoma
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
Carcinoma
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Carcinoma
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Carcinoma, Embryonal
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
Carcinoma, Embryonal
The histone demethylase Kdm3a is essential to progression through differentiation.
Carcinoma, Embryonal
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Carcinoma, Hepatocellular
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Carcinoma, Hepatocellular
Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis.
Carcinoma, Hepatocellular
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Carcinoma, Hepatocellular
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Carcinoma, Hepatocellular
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Carcinoma, Hepatocellular
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
Carcinoma, Hepatocellular
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Carcinoma, Hepatocellular
Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection.
Carcinoma, Hepatocellular
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
Carcinoma, Hepatocellular
[Effect of Basil Polysaccharide on Histone H3K9me2 Methylation and Expression of G9a and JMJD1A in Hepatoma Cells Under Hypoxic Conditions].
Carcinoma, Non-Small-Cell Lung
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Carcinoma, Non-Small-Cell Lung
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Carcinoma, Non-Small-Cell Lung
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
Carcinoma, Non-Small-Cell Lung
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Retraction note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression.
Carcinoma, Renal Cell
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Carcinoma, Renal Cell
KDM3A is not associated with metastasis and prognosis of breast cancer.
Carcinoma, Renal Cell
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
Carcinoma, Squamous Cell
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
Carcinoma, Squamous Cell
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Carcinoma, Squamous Cell
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Carcinoma, Squamous Cell
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Carcinoma, Squamous Cell
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Carcinoma, Squamous Cell
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Cardiomegaly
Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis.
Cardiomegaly
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
Cardiomegaly
The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload.
Cardiomyopathies
Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression.
Cardiomyopathies
Mutations of histone demethylase genes encoded by X and Y chromosomes, Kdm5c and Kdm5d, lead to noncompaction cardiomyopathy in mice.
Cardiomyopathies
Targeting the histone demethylase LSD1 prevents cardiomyopathy in a mouse model of laminopathy.
Cardiomyopathy, Hypertrophic
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
Cardiovascular Diseases
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
CHARGE Syndrome
Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome.
Chickenpox
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Chondrosarcoma
Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas.
Chondrosarcoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Chondrosarcoma
Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.
Colitis
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Colitis
The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells.
Colitis-Associated Neoplasms
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Colonic Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Colonic Neoplasms
Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A.
Colonic Neoplasms
Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.
Colonic Neoplasms
Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer.
Colonic Neoplasms
Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells.
Colonic Neoplasms
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Colonic Neoplasms
Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells.
Colonic Neoplasms
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
Colonic Neoplasms
KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells.
Colonic Neoplasms
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Colonic Neoplasms
Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.
Colonic Neoplasms
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Colonic Neoplasms
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Colonic Neoplasms
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Colonic Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Colonic Neoplasms
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Colonic Neoplasms
[The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells].
Colorectal Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Colorectal Neoplasms
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Colorectal Neoplasms
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Colorectal Neoplasms
Clinical Significance of Histone Demethylase NO66 in Invasive Colorectal Cancer.
Colorectal Neoplasms
Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer.
Colorectal Neoplasms
Correction to: Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Colorectal Neoplasms
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Colorectal Neoplasms
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
Colorectal Neoplasms
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
Colorectal Neoplasms
Histone Demethylase Gene PHF2 Is Mutated in Gastric and Colorectal Cancers.
Colorectal Neoplasms
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Colorectal Neoplasms
Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Colorectal Neoplasms
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Colorectal Neoplasms
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Colorectal Neoplasms
Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.
Colorectal Neoplasms
IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.
Colorectal Neoplasms
JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/?-Catenin Signaling Pathway.
Colorectal Neoplasms
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
Colorectal Neoplasms
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Colorectal Neoplasms
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Colorectal Neoplasms
Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer.
Colorectal Neoplasms
Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer.
Colorectal Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Colorectal Neoplasms
The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer.
Congenital Abnormalities
Lysine demethylase 3a in craniofacial and neural development during Xenopus embryogenesis.
Coronary Artery Disease
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Dehydration
Arabidopsis histone H3K4 demethylase JMJ17 functions in dehydration stress response.
Diabetes Mellitus, Type 2
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Diabetes Mellitus, Type 2
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Diabetic Nephropathies
Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
Diffuse Intrinsic Pontine Glioma
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
Encephalomyelitis
A silent exonic SNP in kdm3a affects nucleic acids structure but does not regulate experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A silent exonic SNP in kdm3a affects nucleic acids structure but does not regulate experimental autoimmune encephalomyelitis.
Endodermal Sinus Tumor
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Endometrial Neoplasms
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Endometriosis
Overexpression of lysine-specific demethylase 1 in ovarian endometriomas and its inhibition reduces cellular proliferation, cell cycle progression, and invasiveness.
Endometriosis
Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Esophageal Neoplasms
MicroRNA let-7i Inhibits Histone Lysine Demethylase KDM5B to Halt Esophageal Cancer Progression.
Esophageal Neoplasms
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Esophageal Squamous Cell Carcinoma
Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells.
Esophageal Squamous Cell Carcinoma
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Esophageal Squamous Cell Carcinoma
Identification and characterization of JMJD2 family genes in silico.
Esophageal Squamous Cell Carcinoma
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
Familial Primary Pulmonary Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Fanconi Anemia
Fanconi Anemia FANCM/FNCM-1 and FANCD2/FCD-2 Are Required for Maintaining Histone Methylation Levels and Interact with the Histone Demethylase LSD1/SPR-5 in
Gallbladder Neoplasms
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
Gastritis
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Gastrointestinal Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Gastrointestinal Stromal Tumors
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Gastrointestinal Stromal Tumors
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Genetic Diseases, Inborn
LSD1/KDM1A mutations associated to a newly described form of intellectual disability impair demethylase activity and binding to transcription factors.
Glioblastoma
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Glioblastoma
Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation.
Glioblastoma
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Glioblastoma
Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1?-dependent pathway.
Glioblastoma
Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3.
Glioblastoma
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Glioblastoma
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Glioma
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Glioma
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma.
Glioma
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Glioma
Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells.
Glioma
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
Glioma
The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling.
Glioma
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells.
Glomerulonephritis
The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis.
Hematologic Diseases
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Hematologic Neoplasms
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
Hepatitis B
The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis.
Herpes Simplex
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
Herpes Simplex
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Herpes Zoster
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Hirschsprung Disease
KDM5B promotes cell migration by regulating the noncanonical Wnt/PCP pathway in Hirschsprung's disease.
Huntington Disease
Systematic genetic interaction studies identify histone demethylase Utx as potential target for ameliorating Huntington's disease.
Hyperalgesia
Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
Hypercholesterolemia
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Hyperglycemia
Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression.
Hyperglycemia
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.
Hyperinsulinism
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Hyperlipidemias
Role of Jhdm2a in regulating metabolic gene expression and obesity resistance.
Hypersensitivity
Arabidopsis histone H3K4 demethylase JMJ17 functions in dehydration stress response.
Hypersensitivity
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Hypertension
Histone demethylase LSD1 and biological sex: impact on blood pressure and aldosterone production.
Hypertension
Histone Demethylase LSD1 Deficiency during High Salt Diet is Associated with Enhanced Vascular Contraction, Altered NO-cGMP Relaxation Pathway, and Hypertension.
Hypertension
Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension.
Hypertension, Pulmonary
Histone demethylase JARID1B regulates proliferation and migration of pulmonary arterial smooth muscle cells in mice with chronic hypoxia-induced pulmonary hypertension via nuclear factor-kappa B (NFkB).
Hypertriglyceridemia
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Infections
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Infections
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
Infections
Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
Infections
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Infections
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
Infections
Role of Serum Amyloid A, Granulocyte-Macrophage Colony-Stimulating Factor, and Bone Marrow Granulocyte-Monocyte Precursor Expansion in Segmented Filamentous Bacterium-Mediated Protection from Entamoeba histolytica.
Infertility
Identification of Two Novel Mutations in KDM3A Regulatory Gene in Iranian Infertile Males
Infertility
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
Infertility
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Infertility, Female
The histone H3K9 demethylase Kdm3b is required for somatic growth and female reproductive function.
Infertility, Male
Association between polymorphisms of exon 12 and exon 24 of JHDM2A gene and male infertility.
Infertility, Male
Evaluation of mRNA Contents of YBX2 and JHDM2A Genes on Testicular Tissues of Azoospermic Men with Different Classes of Spermatogenesis.
Infertility, Male
Identification of Two Novel Mutations in KDM3A Regulatory Gene in Iranian Infertile Males
Infertility, Male
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Inflammatory Bowel Diseases
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Influenza, Human
Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Influenza, Human
Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Intellectual Disability
A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5.
Intellectual Disability
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Intellectual Disability
Crystal structure of the PHF8 Jumonji domain, an Nepsilon-methyl lysine demethylase.
Intellectual Disability
De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism.
Intellectual Disability
Epigenetic regulation in human brain-focus on histone lysine methylation.
Intellectual Disability
Molecular and cellular events linking variants in the histone demethylase KDM5C to the intellectual disability disorder Claes-Jensen syndrome.
Intellectual Disability
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.
Intervertebral Disc Degeneration
microRNA-155-3p attenuates intervertebral disc degeneration via inhibition of KDM3A and HIF1?.
Ischemic Stroke
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Kidney Neoplasms
Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.
Kidney Neoplasms
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Kidney Neoplasms
Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity.
Kidney Neoplasms
In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Kidney Neoplasms
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
Laminopathies
Targeting the histone demethylase LSD1 prevents cardiomyopathy in a mouse model of laminopathy.
Lentivirus Infections
[Knockdown of lysine-specific demethylase 3A (KDM3A) inhibits the invasion and migration of MDA-MB-231 breast cancer cells and arrests the cell cycle in the G0/G1 phase].
Leukemia
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Leukemia
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Leukemia
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Leukemia
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Leukemia
KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.
Leukemia
KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
Leukemia
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
Leukemia
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Leukemia
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia
Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
Leukemia
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Leukemia
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Leukemia
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
Leukemia
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.
Leukemia
[Expression of histone demethylase lysine specific demethylase 1 in acute leukemia and its clinical significance].
Leukemia
[Research Advances in Lysine-specific Demethylase 6A and Its Application in Treating Leukemia].
Leukemia, Erythroblastic, Acute
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia, Lymphocytic, Chronic, B-Cell
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Leukemia, Myeloid
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.
Leukemia, Myeloid, Acute
A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Leukemia, Myeloid, Acute
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Leukemia, Myeloid, Acute
Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.
Leukemia, Myeloid, Acute
Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
Leukemia, Myeloid, Acute
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
Leukemia, Myeloid, Acute
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
Leukemia, Myeloid, Acute
KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
Leukemia, Myeloid, Acute
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Leukemia, Myeloid, Acute
Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
Leukemia, Myeloid, Acute
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Leukemia, Myeloid, Acute
Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
Leukemia, T-Cell
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Liver Cirrhosis
Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor ?
Liver Neoplasms
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Liver Neoplasms
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Liver Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Liver Neoplasms
Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of ?-catenin signaling.
Liver Neoplasms
Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of ?-catenin signaling.
Liver Neoplasms
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Lung Neoplasms
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Lung Neoplasms
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Lung Neoplasms
Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein BRG1.
Lung Neoplasms
Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.
Lung Neoplasms
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Lung Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Lung Neoplasms
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Lung Neoplasms
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
Lung Neoplasms
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Lung Neoplasms
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
Lung Neoplasms
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
Lung Neoplasms
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
Lung Neoplasms
Long noncoding RNA actin filament-associated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer.
Lung Neoplasms
MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1? axis.
Lung Neoplasms
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Lung Neoplasms
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Lung Neoplasms
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
Lung Neoplasms
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
Lung Neoplasms
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Lung Neoplasms
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Lung Neoplasms
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Lung Neoplasms
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Lupus Erythematosus, Systemic
Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Lymphatic Metastasis
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Lymphatic Metastasis
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
Lymphatic Metastasis
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Lymphoma
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Lymphoma, B-Cell
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lymphoma, B-Cell, Marginal Zone
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Lymphoma, Non-Hodgkin
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Mastitis
Lysine-specific demethylase 1 (LSD1) serves as an potential epigenetic determinant to regulate inflammatory responses in mastitis.
Medulloblastoma
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Medulloblastoma
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Melanoma
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Melanoma
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
Melanoma
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
Melanoma
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Memory Disorders
Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse.
Memory Disorders
Environmental enrichment reverses histone methylation changes in the aged hippocampus and restores age-related memory deficits.
Mental Retardation, X-Linked
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C.
Mental Retardation, X-Linked
A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation.
Mental Retardation, X-Linked
A PHF8 homolog in C. elegans promotes DNA repair via homologous recombination.
Mental Retardation, X-Linked
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Mental Retardation, X-Linked
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Mental Retardation, X-Linked
The histone demethylase PHF8 is essential for cytoskeleton dynamics.
Mental Retardation, X-Linked
The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation.
Mesothelioma
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Mesothelioma
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor ? expression in human pleural mesothelioma.
Mesothelioma, Malignant
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Metabolic Syndrome
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Mouth Neoplasms
The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Multiple Myeloma
JMJD2C triggers the growth of multiple myeloma cells via activation of ??catenin.
Multiple Myeloma
Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B.
Myelodysplastic Syndromes
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Myocardial Infarction
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
Myocardial Infarction
Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction.
Myocardial Infarction
The histone demethylase JMJD2B regulates endothelial-to-mesenchymal transition.
Nasopharyngeal Carcinoma
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Nasopharyngeal Carcinoma
Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A.
Neoplasm Metastasis
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Neoplasm Metastasis
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
Neoplasm Metastasis
Bioactivity evaluation of natural product ?-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis.
Neoplasm Metastasis
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Neoplasm Metastasis
Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma.
Neoplasm Metastasis
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Neoplasm Metastasis
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Neoplasm Metastasis
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Neoplasm Metastasis
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Neoplasm Metastasis
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Neoplasm Metastasis
Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Neoplasm Metastasis
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Neoplasm Metastasis
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Neoplasm Metastasis
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Neoplasm Metastasis
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Neoplasm Metastasis
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Neoplasm Metastasis
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Neoplasm Metastasis
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Neoplasm Metastasis
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Neoplasm Metastasis
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Neoplasm Metastasis
Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells.
Neoplasm Metastasis
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Neoplasm Metastasis
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Neoplasm Metastasis
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
Neoplasm Metastasis
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
Neoplasm Metastasis
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
Neoplasm Metastasis
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
Neoplasm Metastasis
KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Neoplasm Metastasis
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Neoplasm Metastasis
KDM3A is not associated with metastasis and prognosis of breast cancer.
Neoplasm Metastasis
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
Neoplasm Metastasis
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Neoplasm Metastasis
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
Neoplasm Metastasis
LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer.
Neoplasm Metastasis
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
Neoplasm Metastasis
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
Neoplasm Metastasis
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Neoplasm Metastasis
Retraction note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Neoplasm Metastasis
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Neoplasm Metastasis
Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Neoplasm Metastasis
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Neoplasm Metastasis
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Neoplasm Metastasis
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
Neoplasm Metastasis
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
Neoplasm Metastasis
[The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells].
Neoplasms
(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.
Neoplasms
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Neoplasms
A developmental genetic analysis of the lysine demethylase KDM2 mutations in Drosophila melanogaster.
Neoplasms
A dual role of dLsd1 in oogenesis: regulating developmental genes and repressing transposons.
Neoplasms
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.
Neoplasms
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Neoplasms
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
Neoplasms
A systematic study of the cellular metabolic regulation of Jhdm1b in tumor cells.
Neoplasms
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Neoplasms
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.
Neoplasms
Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
Neoplasms
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Neoplasms
An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments.
Neoplasms
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
Neoplasms
An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
Neoplasms
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines.
Neoplasms
Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.
Neoplasms
Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.
Neoplasms
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
Neoplasms
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Neoplasms
Bioactivity evaluation of natural product ?-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis.
Neoplasms
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.
Neoplasms
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Neoplasms
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Neoplasms
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Neoplasms
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Neoplasms
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Neoplasms
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Neoplasms
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Neoplasms
Crystal Structure of LSD1 in Complex with 4-[5-(Piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile.
Neoplasms
Crystal Structure of the LSD1/CoREST Histone Demethylase Bound to Its Nucleosome Substrate.
Neoplasms
Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design.
Neoplasms
Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis.
Neoplasms
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Neoplasms
Demethylation of Di-Methylation of Lysine 4 on Histone 3 Is Inhibited by General Control Nondepressible 5-Induced Acetylation of Lysine-Specific Demethylase 1.
Neoplasms
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.
Neoplasms
Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
Neoplasms
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Neoplasms
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Neoplasms
Design, synthesis and evaluation of ?-turn mimetics as LSD1-selective inhibitors.
Neoplasms
Design, synthesis, and biological evaluation of a conjugate of 5-fluorouracil and an LSD1 inhibitor.
Neoplasms
Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating ?,?-Disubstituted Amino Acids with ?-Turn-Inducing Structures.
Neoplasms
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Neoplasms
Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Neoplasms
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Neoplasms
Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Neoplasms
Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Neoplasms
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Neoplasms
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Neoplasms
Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.
Neoplasms
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Neoplasms
Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets.
Neoplasms
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Neoplasms
Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B.
Neoplasms
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Neoplasms
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
Neoplasms
Further insights into the SAR of ?-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A.
Neoplasms
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Neoplasms
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Neoplasms
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Neoplasms
Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells.
Neoplasms
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
Neoplasms
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
Neoplasms
High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Neoplasms
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Neoplasms
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Neoplasms
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Neoplasms
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Neoplasms
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Neoplasms
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Neoplasms
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Neoplasms
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Neoplasms
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Neoplasms
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Neoplasms
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Neoplasms
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Neoplasms
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Neoplasms
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Neoplasms
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Neoplasms
Histone demethylase Jmjd3 modulates osteoblast apoptosis induced by tumor necrosis factor-alpha through directly targeting RASSF5.
Neoplasms
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
Neoplasms
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.
Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Neoplasms
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Neoplasms
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Neoplasms
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Neoplasms
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Neoplasms
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Neoplasms
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Neoplasms
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
Neoplasms
Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Neoplasms
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Neoplasms
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Neoplasms
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Neoplasms
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Neoplasms
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Neoplasms
Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.
Neoplasms
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Neoplasms
Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases.
Neoplasms
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Neoplasms
Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucoyl Spermidine.
Neoplasms
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Neoplasms
Identification of new Wilms tumour predisposition genes: an exome sequencing study.
Neoplasms
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Neoplasms
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Neoplasms
Impairment of Preimplantation Porcine Embryo Development by Histone Demethylase KDM5B Knockdown Through Disturbance of Bivalent H3K4me3-H3K27me3 Modifications.
Neoplasms
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Neoplasms
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
Neoplasms
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Neoplasms
Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
Neoplasms
Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells.
Neoplasms
Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1?-dependent pathway.
Neoplasms
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Neoplasms
Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer.
Neoplasms
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
Neoplasms
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
Neoplasms
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
Neoplasms
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
Neoplasms
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
Neoplasms
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Neoplasms
JMJD1B, a novel player in histone H3 and H4 processing to ensure genome stability.
Neoplasms
JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells.
Neoplasms
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Neoplasms
JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy.
Neoplasms
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
Neoplasms
JMJD2C triggers the growth of multiple myeloma cells via activation of ??catenin.
Neoplasms
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Neoplasms
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Neoplasms
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
Neoplasms
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Neoplasms
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
Neoplasms
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
Neoplasms
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Neoplasms
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
Neoplasms
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
Neoplasms
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
Neoplasms
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Neoplasms
KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.
Neoplasms
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
Neoplasms
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
Neoplasms
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Neoplasms
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Neoplasms
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
Neoplasms
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Neoplasms
KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
Neoplasms
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
Neoplasms
KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-?1 expression.
Neoplasms
Kinetic analysis of iron-dependent histone demethylases: ?-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells.
Neoplasms
Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer.
Neoplasms
Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation.
Neoplasms
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Neoplasms
Loss of lysine-specific demethylase 1 nonautonomously causes stem cell tumors in the Drosophila ovary.
Neoplasms
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Neoplasms
Low Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1.
Neoplasms
LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer.
Neoplasms
LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter.
Neoplasms
LSD1 demethylates HIF1? to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis.
Neoplasms
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.
Neoplasms
LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors.
Neoplasms
LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer.
Neoplasms
LSD1 modulates the non-canonical integrin ?3 signaling pathway in non-small cell lung carcinoma cells.
Neoplasms
LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.
Neoplasms
LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
Neoplasms
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
Neoplasms
Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies.
Neoplasms
Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers.
Neoplasms
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Neoplasms
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Neoplasms
Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1? and microRNA-146a.
Neoplasms
Lysine-specific demethylase 1 inhibition enhances autophagy and attenuates early-stage post-spinal cord injury apoptosis.
Neoplasms
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Neoplasms
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells.
Neoplasms
Lysine-specific demethylase-1 regulates fibroblast activation in pulmonary fibrosis via TGF-?1/Smad3 pathway.
Neoplasms
Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1.
Neoplasms
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Neoplasms
Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
Neoplasms
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Neoplasms
microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
Neoplasms
MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation.
Neoplasms
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
Neoplasms
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
Neoplasms
MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition.
Neoplasms
Molecular cloning, tissue expression, and analysis with genome DNA methylation of porcine LSD1 gene.
Neoplasms
Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Neoplasms
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells.
Neoplasms
Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.
Neoplasms
Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype.
Neoplasms
Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
Neoplasms
Oncogenic KRAS sensitizes lung adenocarcinoma to GSK-J4-induced metabolic and oxidative stress.
Neoplasms
Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer.
Neoplasms
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Neoplasms
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Neoplasms
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Neoplasms
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Neoplasms
p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo.
Neoplasms
Pathophysiological Response to Hypoxia - From the Molecular Mechanisms of Malady to Drug Discovery:Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes.
Neoplasms
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Neoplasms
PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.
Neoplasms
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Neoplasms
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Neoplasms
Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A.
Neoplasms
Regulation of the Histone Demethylase JMJD1A by HIF-1{alpha} Enhances Hypoxic Gene Expression and Tumor Growth.
Neoplasms
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Neoplasms
Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.
Neoplasms
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth.
Neoplasms
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Neoplasms
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Neoplasms
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Neoplasms
Simultaneous Inhibition of LSD1 and TGF? Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Neoplasms
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Neoplasms
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Neoplasms
Stable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiation.
Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Neoplasms
Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Neoplasms
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Neoplasms
Structure-Based Design of a New Scaffold for Cell-Penetrating Peptidic Inhibitors of the Histone Demethylase PHF8.
Neoplasms
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Neoplasms
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells.
Neoplasms
Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Neoplasms
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Neoplasms
Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Neoplasms
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Neoplasms
Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
Neoplasms
Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
Neoplasms
Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells.
Neoplasms
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Neoplasms
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Neoplasms
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Neoplasms
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
Neoplasms
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
Neoplasms
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
Neoplasms
The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
Neoplasms
The histone demethylase Jarid1b is required for hematopoietic stem cell self-renewal.
Neoplasms
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
Neoplasms
The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability.
Neoplasms
The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
Neoplasms
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
Neoplasms
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Neoplasms
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Neoplasms
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
Neoplasms
The histone demethylase Kdm3a is required for normal epithelial proliferation, ductal elongation and tumor growth in the mouse mammary gland.
Neoplasms
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
Neoplasms
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Neoplasms
The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Neoplasms
The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells.
Neoplasms
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
Neoplasms
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Neoplasms
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
Neoplasms
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
Neoplasms
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
Neoplasms
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Neoplasms
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
Neoplasms
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
Neoplasms
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Neoplasms
The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
Neoplasms
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
Neoplasms
The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN.
Neoplasms
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
Neoplasms
The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.
Neoplasms
The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) In Cancers: Current Progress and Future Perspectives.
Neoplasms
The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells.
Neoplasms
The Siah2-HIF-FoxA2 axis in prostate cancer - new markers and therapeutic opportunities.
Neoplasms
The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase.
Neoplasms
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Neoplasms
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Neoplasms
Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT.
Neoplasms, Germ Cell and Embryonal
Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.
Neuralgia
MiR-216a-5p alleviates chronic constriction injury-induced neuropathic pain in rats by targeting KDM3A and inactivating Wnt/?-catenin signaling pathway.
Neuralgia
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Neuroblastoma
Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation.
Neuroblastoma
Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
Neuroblastoma
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Neuroblastoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Neuroblastoma
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Neuroblastoma
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Neuroblastoma
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Neuroblastoma
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.
Neuroblastoma
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Neuroblastoma
The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Neurodegenerative Diseases
Targeting Histone Demethylase LSD1/KDM1a in Neurodegenerative Diseases.
Neurofibrosarcoma
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Neuroinflammatory Diseases
RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to inflammation mediated by the selective jumonji H3K27 demethylase inhibitor.
Non-alcoholic Fatty Liver Disease
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Non-alcoholic Fatty Liver Disease
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Obesity
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Obesity
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Obesity
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Obesity
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Obesity
Regulation of adipogenesis by nuclear receptor PPAR? is modulated by the histone demethylase JMJD2C.
Obesity
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Oligospermia
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
Oropharyngeal Neoplasms
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Osteoarthritis, Knee
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Osteosarcoma
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
Osteosarcoma
Correction to: microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
Osteosarcoma
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Osteosarcoma
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Osteosarcoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Osteosarcoma
microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
Osteosarcoma
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Ovarian Neoplasms
Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.
Ovarian Neoplasms
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines.
Ovarian Neoplasms
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Ovarian Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Ovarian Neoplasms
Histone Demethylase KDM4C Is Required for Ovarian Cancer Stem Cell Maintenance.
Ovarian Neoplasms
Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells.
Ovarian Neoplasms
LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
Ovarian Neoplasms
Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells.
Ovarian Neoplasms
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells.
Ovarian Neoplasms
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ovarian Neoplasms
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Pancreatic Neoplasms
circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer.
Pancreatic Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Pancreatic Neoplasms
Incorporating multiple sets of eQTL weights into gene-by-environment interaction analysis identifies novel susceptibility loci for pancreatic cancer.
Pancreatic Neoplasms
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Pancreatic Neoplasms
Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP?
Pancreatic Neoplasms
PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells.
Pancreatic Neoplasms
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Parkinson Disease
Therapeutic effect of a histone demethylase inhibitor in Parkinson's disease.
Persistent Infection
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Polycythemia Vera
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Pre-Eclampsia
Compromised JMJD6 histone demethylase activity impacts on VHL gene repression in preeclampsia.
Pre-Eclampsia
Overexpression of let-7d explains down-regulated KDM3A and ENO2 in the pathogenesis of preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Prostatic Neoplasms
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.
Prostatic Neoplasms
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Prostatic Neoplasms
c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Prostatic Neoplasms
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Prostatic Neoplasms
Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Prostatic Neoplasms
Downregulation of lysine-specific demethylase 1 enhances the sensitivity of hormone-sensitive prostate cancer cells to androgen deprivation therapy.
Prostatic Neoplasms
EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.
Prostatic Neoplasms
Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Prostatic Neoplasms
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
Prostatic Neoplasms
Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells.
Prostatic Neoplasms
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Prostatic Neoplasms
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
Prostatic Neoplasms
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
Prostatic Neoplasms
Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Prostatic Neoplasms
Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Prostatic Neoplasms
KDM3A is not associated with metastasis and prognosis of breast cancer.
Prostatic Neoplasms
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Prostatic Neoplasms
Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Prostatic Neoplasms
LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6.
Prostatic Neoplasms
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Prostatic Neoplasms
NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy.
Prostatic Neoplasms
NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Prostatic Neoplasms
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
Prostatic Neoplasms
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Prostatic Neoplasms
p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
Prostatic Neoplasms
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Prostatic Neoplasms
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Prostatic Neoplasms
Role of UTX Histone Demethylase in Regulation of MGMT, TRA2A, U2AF1, and RPS6KA2 Genes in Prostate Cancer Cell Lines.
Prostatic Neoplasms
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Prostatic Neoplasms
Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer.
Prostatic Neoplasms
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer.
Prostatic Neoplasms
Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
Prostatic Neoplasms
The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Prostatic Neoplasms
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
Prostatic Neoplasms
The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b.
Prostatic Neoplasms
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Prostatic Neoplasms
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.
Respiratory Insufficiency
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3.
Retinal Diseases
Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases.
Retinoblastoma
Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp.
Retinoblastoma
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Retinoblastoma
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Retinoblastoma
Histone demethylase retinoblastoma binding protein 2 regulates the expression of ?-smooth muscle actin and vimentin in cirrhotic livers.
Retinoblastoma
Inhibition of osteogenic differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 repression of RUNX2-activated transcription.
Retinoblastoma
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Retinoblastoma
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
Retinoblastoma
Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells.
Rhabdomyosarcoma
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Rhabdomyosarcoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Rhabdomyosarcoma
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Rhabdomyosarcoma
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells.
Rhabdomyosarcoma
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Sarcoma
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Sarcoma
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma, Ewing
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Sarcoma, Ewing
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth.
Sarcoma, Ewing
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Sarcoma, Ewing
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
Sarcoma, Ewing
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Sarcoma, Ewing
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
Sarcoma, Ewing
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
Sarcoma, Synovial
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Sarcoma, Synovial
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Scleroderma, Systemic
The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.
Seminoma
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Sepsis
GSKJ4 Protects Mice Against Early Sepsis via Reducing Proinflammatory Factors and Up-Regulating MiR-146a.
Shock, Septic
Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shock.
Small Cell Lung Carcinoma
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Solitary Fibrous Tumors
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Spondylitis, Ankylosing
The histone demethylase JARID1A is associated with susceptibility to ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
Squamous Cell Carcinoma of Head and Neck
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Squamous Cell Carcinoma of Head and Neck
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Starvation
A CxxC Domain That Binds to Unmethylated CpG Is Required for KDM2A to Control rDNA Transcription.
Starvation
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Starvation
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Starvation
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
Starvation
JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy.
Stomach Neoplasms
Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.
Stomach Neoplasms
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Stomach Neoplasms
Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.
Stomach Neoplasms
Expression pattern of histone lysine-specific demethylase 6B in gastric cancer.
Stomach Neoplasms
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Stomach Neoplasms
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Stomach Neoplasms
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.
Stomach Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Stomach Neoplasms
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Stomach Neoplasms
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Stomach Neoplasms
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Stomach Neoplasms
Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
Stomach Neoplasms
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Stomach Neoplasms
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
Stomach Neoplasms
KDM3A interacted with p53K372me1 and regulated p53 binding to PUMA in gastric cancer.
Stomach Neoplasms
Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.
Stomach Neoplasms
Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803.
Stomach Neoplasms
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
Stomach Neoplasms
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
Stomach Neoplasms
shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway.
Stomach Neoplasms
Targeting the histone demethylase PHF8-mediated PKC?-Src-PTEN axis in HER2-negative gastric cancer.
Stomach Neoplasms
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
Stomach Neoplasms
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Teratocarcinoma
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Teratoma
Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells.
Teratozoospermia
Kdm3a lysine demethylase is an Hsp90 client required for cytoskeletal rearrangements during spermatogenesis.
Testicular Neoplasms
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Thyroid Cancer, Papillary
Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells.
Thyroid Cancer, Papillary
Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1? and microRNA-146a.
Thyroid Cancer, Papillary
microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.
Tics
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.
Tongue Neoplasms
High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Triple Negative Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Triple Negative Breast Neoplasms
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Triple Negative Breast Neoplasms
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Ureteral Obstruction
Lysine-specific demethylase 1 induced epithelial-mesenchymal transition and promoted renal fibrosis through Jagged-1/Notch signaling pathway.
Urinary Bladder Neoplasms
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Urinary Bladder Neoplasms
Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21.
Urinary Bladder Neoplasms
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Urinary Bladder Neoplasms
Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Urinary Bladder Neoplasms
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Urinary Bladder Neoplasms
Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
Urinary Bladder Neoplasms
Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer.
Urinary Bladder Neoplasms
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Urinary Bladder Neoplasms
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
Uterine Cervical Neoplasms
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Uterine Cervical Neoplasms
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
Uterine Neoplasms
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Vascular System Injuries
Critical role of histone demethylase JMJD3 in the regulation of neointima formation following vascular injury.
Vascular System Injuries
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Virus Diseases
Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Virus Diseases
Histone demethylase LSD1 regulates hematopoietic stem cells homeostasis and protects from death by endotoxic shock.
Virus Diseases
Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Virus Diseases
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Virus Diseases
T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX.
[histone h3]-n6,n6-dimethyl-l-lysine4 fad-dependent demethylase deficiency
Histone Demethylase LSD1 Deficiency during High Salt Diet is Associated with Enhanced Vascular Contraction, Altered NO-cGMP Relaxation Pathway, and Hypertension.
[histone h3]-trimethyl-l-lysine4 demethylase deficiency
Effect of histone demethylase KDM5A on the odontogenic differentiation of human dental pulp cells.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Rescuing the aberrant sex development of H3K9 demethylase Jmjd1a-deficient mice by modulating H3K9 methylation balance.
html completed